找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Breast Disease; Management and Thera Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019Latest edition Springer Nature Switzerland AG 2019 b

[復(fù)制鏈接]
樓主: Weber-test
51#
發(fā)表于 2025-3-30 10:52:08 | 只看該作者
Rui Liu,Feilong Bao,Guanglai Gao,Yonghe Wange “oncoplastic breast surgery (OBS)” concept has come into consideration among breast surgeons in the last two decades. The aim of OBS is to make no compromise from oncologic principles for a better cosmetic result. The tumor cavity is filled with the remaining breast tissue (volume displacement tec
52#
發(fā)表于 2025-3-30 15:27:56 | 只看該作者
Research on Telegrapher Selectionaxilla can become negative in up to 60% of cases depending on tumor biology, and SLNB can be performed with a low false-negative rate either using the targeted (clip-seed) technique or in the classic fashion (lympho-blue dye). In patients with positive SLNB (with limited involvement) after neoadjuva
53#
發(fā)表于 2025-3-30 16:53:28 | 只看該作者
Haijing Song,Li Han,Hongjiao Wus with tamoxifen in premenopausal and postmenopausal women, lowering systemic estrogen levels with luteinizing hormone-releasing hormone agonists in premenopausal women, or blocking estrogen biosynthesis in nonovarian tissues with aromatase inhibitors in postmenopausal women.
54#
發(fā)表于 2025-3-30 21:23:34 | 只看該作者
Man-Machine-Environment System Engineeringgimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo
55#
發(fā)表于 2025-3-31 03:54:01 | 只看該作者
Shengzhao Long,Balbir S. Dhillonnts with HER-2-positive early breast cancer. Thus, the monoclonal antibody trastuzumab has been approved as the first and only molecularly targeted agent for the adjuvant treatment of HER-2-positive breast cancer. Despite tremendous progress in the treatment of HER-2-positive breast cancer, many que
56#
發(fā)表于 2025-3-31 09:02:19 | 只看該作者
57#
發(fā)表于 2025-3-31 12:41:48 | 只看該作者
Chenming Li,Tianhao Wang,Yuhong ShenC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a
58#
發(fā)表于 2025-3-31 16:14:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 12:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
六安市| 乐山市| 军事| 合肥市| 资阳市| 张家港市| 沙河市| 衢州市| 永修县| 建德市| 北辰区| 东丽区| 泽州县| 呼和浩特市| 昭通市| 博白县| 西平县| 农安县| 和硕县| 宜兰市| 宜春市| 科技| 敦化市| 革吉县| 大余县| 宜城市| 永川市| 邢台县| 乌兰浩特市| 德化县| 阳山县| 永仁县| 手机| 浑源县| 洞头县| 锦州市| 大石桥市| 博客| 雷山县| 年辖:市辖区| 吉木萨尔县|